The Prognostic Value and Immunomodulatory Role of Spsb2, a Novel Immune Checkpoint Molecule, in Hepatocellular Carcinoma.

Lv Tian, Yiming Wang, Jiexin Guan, Lu Zhang, Jun Fan

Abstract read

In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lv TianInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 611731, China.

Yiming WangSchool of Nursing, Jilin University, Changchun 130021, China.

Jiexin GuanInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 611731, China.

Lu ZhangInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 611731, China.

Jun FanInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu 611731, China.ORCID 0000-0002-1433-7283

Funding

Sichuan Science & Technology Program No. 2023NSFSC0638

6 · The paper itself

Abstract

backgroundLiver cancer, specifically hepatocellular carcinoma (LIHC), ranks as the second most common cause of cancer-related fatalities globally. Moreover, the occurrence rate of LIHC is steadily increasing. A recently identified gene,

methodsUsing the TCGA, GTEx, and GEO databases, we obtained differentially expressed genes that affect the prognosis of patients with LIHC. We utilized the Kruskal-Wallis test, along with univariate and multivariate COX regression analyses, to determine the correlation between SPSB2 and patient clinical indicators. Potential biological functions of SPSB2 in LIHC were explored by enrichment analysis, ssGSEA, and Spearman correlation analysis. Finally, LIHC cell lines Huh7 and SMMC-7721 were used to validate the biological function of SPSB2.

resultsThe results showed LIHC patients with higher SPSB2 expression had a poorer prognosis, and SPSB2 expression was significantly correlated with LIHC patients' Histologic grade, Pathologic T stage, Prothrombin time, Pathologic stage, BMI, weight, adjacent hepatic tissue inflammation, AFP level, and OS event (

conclusionsSPSB2 plays a crucial role in the development of LIHC. It is related to the immune response and unfavorable outcomes. SPSB2 may function as a clinical biomarker for prognosis.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularImmune Checkpoint ProteinsLiver NeoplasmsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorImmune Checkpoint Proteinsbiomarkershepatocellular carcinomaimmune checkpointsimmune infiltrationprognosisSPSB2

Identifiers

PMID40149497

DOI10.3390/genes16030346

PMCPMC11941779

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.